Press Release
Vasomedical to Expand European Marketing Presence
Company to Exhibit Its EECP System At Three Major Cardiovascular Conferences in Europe
WESTBURY, N.Y.--(BW HealthWire)--April 19, 2001--Vasomedical, Inc. (Nasdaq: VASO - news) announced today that it will present its EECP® enhanced external counterpulsation therapy system at three major cardiovascular conferences in Europe this spring.
These include the British Cardiac Society in Manchester, United Kingdom, May 22-24, where the results of several clinical studies demonstrating the efficacy of EECP will be presented. The company will also present its EECP system at the Euro-Paris Course on Revascularization in Paris, France, May 22-25; and the European Society of Cardiology's Heart Failure Conference in Barcelona, Spain, June 9-12. Total attendance by clinicians at the three conferences is expected to exceed 10,000.
``Participation in these conferences is part of the company's accelerated efforts to expand and build upon previously established research and distribution relationships in Europe,'' said D. Michael Deignan, President and CEO of Vasomedical. ``Our recent experience at the American College of Cardiology (ACC) confirms that interest in EECP is growing on a global basis. The market potential for EECP systems in Europe is comparable to that of the United States. We are now creating the necessary infrastructure to capitalize on this opportunity. To that end, the company expects to retain its first Europe-based executive later this spring.''
The company estimates there are approximately 10 million people currently suffering from angina in the European Community. This compares to about 7 million in the United States. EECP is a non-invasive, outpatient therapy for angina that utilizes pneumatic cuffs to compress the lower extremities in time with a patient's heartbeat. The therapy reduces levels of angina by improving circulation in areas of the heart deprived of adequate blood supply and restoring vascular function. The therapy has been scientifically validated over the past several years, and has been approved for Medicare reimbursement in the United States.
The company has already established a working relationship in the UK and several other markets for the service and support of equipment, and plans to establish additional marketing and infrastructure arrangements (including both service and clinical application support) in near future. Vasomedical has been awarded the CE mark allowing it to market EECP throughout Europe for the treatment of angina and coronary artery disease.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counter pulsation systems based on the Company's proprietary technology currently indicated for use in cases of angina, cardiogenic shock and acute myocardial infarction. EECP® is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Beth Israel Medical Center - New York City, Christ Hospital and Medical Center, the Cleveland Clinic, Texas Heart Institute, Johns Hopkins, JFK Medical Center-Atlantis, FL, University Hospital at UMDNJ/New Jersey Medical School, the Mayo Clinic, the Miami Heart Institute and the Ochsner Foundation Hospital, as well as medical centers affiliated with Columbia University, the University of Pittsburgh, the University of California at San Diego, the University of California at San Francisco, University of Florida at Gainesville, State University of New York at Stony Brook and the University of Virginia. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward looking statements that involve risks and uncertainties. When used in this release, words such as ``anticipate,'' ``believe,'' ``estimate,'' ``expect'' and ``intend'' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.
--------------------------------------------------------------------------------
Contact:
Vasomedical, Inc., Westbury
D. Michael Deignan, President & CEO
516/997-4600 Ext. 155
Douglas A. Goldman, VP of Marketing
& Business Development
516/997-4600 Ext. 163
www.vasomedical.com
or
INVESTOR RELATIONS:
516/997-4600 x 790
investorrelations@vasomedical.com |
